Skip to content
Open access

181. Integrating clinical profiles and microRNAs to uncover molecular mechanisms in treatment-resistant schizophrenia

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i5 - i5 · 0 citations

TL;DR

Findings suggest that increased expression of these miRNAs may enhance gene silencing across synaptic and intracellular signaling cascades, potentially contributing to impaired neuroplasticity and treatment resistance through downregulation of critical neurotransmission-related targets.

Abstract

Abstract Background Treatment-resistant schizophrenia (TRS), defined as the persistence of symptoms despite adequate antipsychotic treatment, remains frequently underrecognized, with clozapine, the gold standard, introduced only after an average delay of 4–9 years. In this study, we aimed to identify which Positive and Negative Syndrome Scale (PANSS) factors, executive function measures, and selected microRNAs (miRNAs) are most strongly associated with TRS, and to investigate the molecular underpinnings targeted by these miRNAs, thereby hypothesizing aberrant mechanisms contributing to the TRS condition. Aims & Objectives This study sought to (i) identify clinical (PANSS and executive function) and circulating miRNA features associated with TRS, (ii) integrate these features via machine learning to define a predictive signature, and (iii) investigate biological pathways regulated by TRS-related miRNAs to uncover mechanisms contributing to treatment resistance. Method We examined 60 patients with schizophrenia (25 treatment-responsive, 35 TRS) following a structured retrospective-prospective evaluation of antipsychotic response. Seventeen serum miRNAs were assessed. Principal Component Analysis (PCA) identified clinical variables and miRNAs with loading scores ≥ 0.4, which were used to train three machine learning models. Random Forest (RF) provided the best balance of accuracy, sensitivity, specificity, and generalizability. Based on RF with nested cross-validation, selected miRNAs underwent Gene Ontology (GO) and KEGG enrichment analyses with Benjamini–Hochberg correction. Results PCA highlighted PANSS emotional (EMO), disorganization (DIS), and excitement (EXC) factors, processing speed, and miRNAs (miR-132-3p, miR-181-5p, miR-203a-3p, miR-199a-5p, miR-128-3p). RF classified TRS patients based on higher EMO, DIS, EXC, miR-132-3p, miR-181-5p, and miR-203a-3p, with 62.9% sensitivity, 60% specificity, and 0.71 AUC. GO analysis indicated that miR-132, miR-181b, and miR-203a regulate stress response, apoptosis, cell cycle, differentiation, and protein homeostasis, converging on synaptic signaling and neuroplasticity pathways (ErbB, glutamatergic, dopaminergic ones). MiR-132 targets were enriched in processes related to stress response, nutrient sensing, and DNA damage signaling, with localization at the apicolateral membrane and functions in ubiquitin-ligase and kinase regulation, indicating a role in protein homeostasis and signaling modulation. MiR-181b targets were primarily associated with extrinsic apoptosis, negative regulation of cell growth, G1/S transition, and transcriptional repression, suggesting involvement in cell survival and proliferation control. MiR-203a targets showed enrichment in intrinsic apoptosis, neuronal apoptosis, oxidative-stress response, and differentiation pathways, including neuronal development, further implicating this miRNA in cell survival and neurodevelopmental processes. Enrichment analyses showed that the TRS-associated miRNAs converged on core schizophrenia-related pathways. miR-132 was strongly enriched in ErbB and glutamatergic signaling, while miR-181b and miR-203a showed robust enrichment in dopaminergic synapse and ErbB pathways, regulating key neuroplasticity and neurotransmission genes (e.g., MAPK, AKT, GRIN2, HOMER, COMT). These findings suggest that increased expression of these miRNAs may enhance gene silencing across synaptic and intracellular signaling cascades, potentially contributing to impaired neuroplasticity and treatment resistance through downregulation of critical neurotransmission-related targets. Predicted targets included key neurotransmission genes (DRD1, HOMER1, MAPK1/3, GRIN2A/D), also modulated by antipsychotics. Discussion & Conclusions TRS is characterized by a combined clinical-molecular signature involving PANSS domains, and selected miRNAs converging on synaptic and neuroplasticity networks. Dopaminergic, glutamatergic and ErbB pathways emerged as central hubs, suggesting that antipsychotic effects may be mediated, at least in part, through miRNA-driven mechanisms underlying TRS.

Read PDF

Similar papers

Review Open access Sep 2026

856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies

Abstract Background Antipsychotic monotherapy is the guideline-supported mainstay of treatment for schizophrenia. However, approximately 40% of patients fail to achieve an adequate response in randomized controlled trials, highlighting the significant clinical challenge of treatment-resistant schizophrenia (TRS). Despi...

M. Samara · 0 citations
Open access Sep 2026

526. Translating glutamate modulation into clinical advances for patients with treatment-resistant schizophrenia: challenges and updates from the ENIGMA-TRS phase 3 program

The goal is to generate reliable data supporting evenamide as an effective alternative for treating TRS, and to present challenges in the design and implementation of ENIGMA-TRS, the largest phase 3 clinical program ever designed for patients with TRS.

R. Anand, A. Turolla, G. Chinellato et al. · 0 citations
Open access Sep 2026

563. Plasma interleukin-6 levels in antipsychotic-responsive and treatment-resistant schizophrenia in association with clozapine treatment

Abstract Background Neuroinflammation has been proposed as a key pathophysiological mechanism underlying treatment-resistant schizophrenia (TRS). Interleukin-6 (IL-6) has been reported as a trait-related inflammatory marker in schizophrenia; however, data focusing specifically on TRS and the impact of clozapine treatme...

Y. Suzuki, K. Endo, S. Yokokawa et al. · 0 citations
Oct 2026

Plasma interleukin-6 levels and treatment responses to antipsychotics in schizophrenia: Focus on clozapine treatment.

Neuroinflammation is a key pathophysiological mechanism underlying treatment-resistant schizophrenia (TRS). Interleukin (IL)-6 is a trait-related biomarker that exhibits consistently elevated levels in schizophrenia. However, studies focusing on TRS and examining the associations of clozapine treatment with inflammator...

Yuhei Suzuki, Kota Endo, Shuuho Yokokawa et al. · 0 citations
Open access Sep 2026

708. From molecules to meaning: metabolomic and transcriptomic pathways to overcoming treatment resistance

Findings support a clinically relevant bridge between molecular biology and treatment efficacy: multi-omics signatures can clarify mechanistic drivers of resistance, enable patient stratification beyond diagnosis, and provide predictive biomarkers suitable for decision support.

B. Baune · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.